The Impact Of Periodontal Disease Treatment On The General Health Status In Chronic Haemodialyzed Patients (PAROHEM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01785355|
Recruitment Status : Recruiting
First Posted : February 7, 2013
Last Update Posted : July 23, 2019
|Condition or disease||Intervention/treatment|
|Periodontal Disease Chronic Kidney Disease||Other: Dental treatment|
Patients will be recruited according to eligibility criteria. Initial oral and general status will be evaluated and recorded. The evaluated parameters are listed at the study description section. Also, quality of life will be assessed by using the SF-36 and OHIP-14 questionnaires.
Patients will undergo a series of dental interventions with the final scope of eliminating all oral inflammation. Participants will also be instructed regarding correct oral hygiene habits.
Following dental and periodontal treatments, the oral and general status will be reassessed and the obtained dat analysed.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Periodontal Disease, Inflammation, Nutritional Status And Anaemia Response To Erythropoietin In Chronic Haemodialyzed Patients - The Impact Of Treatment For Periodontal Disease|
|Actual Study Start Date :||September 2012|
|Estimated Primary Completion Date :||September 2021|
|Estimated Study Completion Date :||June 2022|
Assessment of the clinical state of the patient. Professional prophylaxis and removal of calculus. Extraction of hopeless teeth.Education of patient for oral hygiene. Periodic reevaluation.
Other: Dental treatment
- Modification of nutritional status [ Time Frame: 6 months ]SGA, whole body bioimpedance, biochemical parameters (serum albumin, predialysis serum urea, serum creatinine, serum phosphates)
- Modification of inflammatory status [ Time Frame: 6 months ]C Reactive Protein
- Modification of periodontal disease index [ Time Frame: 3 months ]Modification of periodontal disease index assessed by the CAL, PPD, bleeding index
- Modification of the quality of life, as assessed by SF-36 and OHIP-14 [ Time Frame: 6 months ]Modification of the quality of life, as assessed by SF-36 and OHIP-14
- Modification of anaemia response to epoetin [ Time Frame: 6 months ]Modification of anaemia response to epoetin, as assessed by the ERI and by the cumulative ESAs dose
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01785355
|Contact: Oana Slusanschi, DMDfirstname.lastname@example.org|
|Contact: Liliana Garneata, MDemail@example.com|
|CMI "Dr Slusanschi Oana"||Recruiting|
|Contact: Oana Slusanschi, DMD +40722266279 firstname.lastname@example.org|
|Principal Investigator: Oana Slusanschi, DMD|
|Principal Investigator:||Oana Slusanschi, DMD||University of Medicine and Pharmacy Bucharest|